---
title: "Arcellx (ACLX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ACLX.US.md"
symbol: "ACLX.US"
name: "Arcellx"
industry: "Biotechnology"
datetime: "2026-05-20T06:52:27.727Z"
locales:
  - [en](https://longbridge.com/en/quote/ACLX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ACLX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ACLX.US.md)
---

# Arcellx (ACLX.US)

## Company Overview

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: D (0.77)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -79.35% |  |
| Net Profit YoY | -113.26% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 22286000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -53.42% | E |
| Profit Margin | -1027.25% | E |
| Gross Margin | -607.22% | E |
| Revenue YoY | -79.35% | E |
| Net Profit YoY | -113.26% | E |
| Total Assets YoY | -15.09% | E |
| Net Assets YoY | -11.53% | E |
| Cash Flow Margin | 91.84% | C |
| OCF YoY | -79.35% | E |
| Turnover | 0.03 | E |
| Gearing Ratio | 33.38% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Arcellx",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-79.35%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-113.26%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "22286000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-53.42%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1027.25%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-607.22%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-79.35%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-113.26%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-15.09%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-11.53%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "91.84%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-79.35%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.03",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "33.38%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -29.39 | 518/386 | - | - | - |
| PB | 16.72 | 410/386 | 16.62 | 9.88 | 8.78 |
| PS (TTM) | 301.95 | 285/386 | 300.09 | 104.25 | 51.04 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-02T04:00:00.000Z

Total Analysts: **18**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 18 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 115.07 |
| Highest Target | 120.00 |
| Lowest Target | 82.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ACLX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ACLX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ACLX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ACLX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**